Bristol-Myers Squibb confirms closure of Wallingford site

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

HARTFORD – A global biopharmaceutical company confirmed plans to close its location in Wallingford by the end of 2018.

Bristol-Myers Squibb Company confirmed the previously announced plans to close the company’s Wallingford site and also announced it will no longer build a ‘Connecticut development’ site.

The company said their domestic footprint will be focus on Central New Jersey, the San Francisco Bay Area and Cambridge, Massachusetts.

The company will also be phasing out a location in Hopewell, New Jersey, and not renewing a lease at its Lake Union Steam Plant site in Seattle, Washington.

The company said it expects that many of the roles from Wallingford, Hopewell and Seattle will transition to other U.S. locations.